Physician profile
Mark Garcia
NPI 1942260088
$484,436.62
in general payments reported to CMS, 2019-2025
30 companies · $4,458 in 2025
The $4,458 reported for 2025 was more than what 84% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $42K · 2021: $292K · 2022: $46K · 2023: $39K · 2024: $1,267 · 2025: $4,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Royalty Or License: $8,101 · Food and Beverage: $1,913 · Travel and Lodging: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,000.00 |
| Royalty Or License | $8,100.51 |
| Food and Beverage | $1,913.22 |
| Travel and Lodging | $906.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $249,252.01 | 2021-2024 | Abre, Venaseal |
| Vesper Medical | $120,000.00 | 2020-2023 | Duo Venous Stent System |
| Ekos Corporation | $49,223.76 | 2019 | |
| Merit Medical Systems INC | $41,519.68 | 2019-2025 | Revolution Cath Securemnt Dev |
| Cagent Vascular INC | $9,722.87 | 2021-2025 | Serrantor |
| Abbott Laboratories | $3,728.47 | 2019-2025 | Esprit |
| Janssen Pharmaceuticals, INC | $3,598.87 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $1,901.35 | 2019-2024 | Ekosonic, Angiojet Ultra 5000a |
| Philips North America LLC | $1,349.77 | 2019-2022 | |
| Endologix LLC | $1,165.75 | 2019-2024 | Endocross Device, Torus Stent Graft System |
| Bard Peripheral Vascular, INC. | $1,013.35 | 2019-2025 | Crosser Iq, Rotarexs 6 F X 135 Cm, Venovo |
| Medtronic Vascular, INC. | $324.10 | 2019 | |
| Angiodynamics, INC. | $257.65 | 2020-2025 | Auryon Laser System 100-120 Vac |
| Cardiovascular Systems INC. | $200.68 | 2020-2022 | |
| Siemens Medical Solutions USA, INC. | $178.31 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $140.61 | 2022 | |
| Nevro Corp. | $127.89 | 2024 | Senza |
| Penumbra, INC. | $111.75 | 2024 | Indigo System, Penumbra System |
| Cook Medical LLC | $99.44 | 2019-2023 | Torcon Nb, Tornado |
| E.R. Squibb & Sons, L.L.C. | $96.20 | 2019-2022 | |
| Avinger INC. | $89.61 | 2019-2022 | |
| Cashflow Solutions, LLC | $84.62 | 2023-2024 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Terumo Medical Corporation | $73.29 | 2019-2023 | Glidewire, Angio-Seal, R2p Misago |
| Reflow Medical INC | $59.99 | 2024-2025 | |
| Tactile Systems Technology INC | $33.72 | 2025 | Nimbl, Flexitouch Plus |
| Teleflex LLC | $22.21 | 2025 | Arrow |
| Resmed Corp | $17.06 | 2023 | |
| Intact Vascular, INC. | $16.00 | 2019 | |
| Cardinal Health 200 LLC | $15.95 | 2019 | |
| Pfizer INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.